In Week of Mar 28, 2026, Bliss GVS Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +42.4% relative strength. Fundamentals: Average. On a 9-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Strong 9M performance with 15.13% revenue growth and 32.78% PAT growth expected to drive full-year results
Impact: +₹10 Cr revenue
“Nine-month consolidated operations showed strong growth with 32.78% increase in net profit to ₹9,772.90 lakh and 15.13% revenue growth to ₹73,248.81 lakh”
What: Interest costs declining to ₹1.49 cr from ₹3.04 cr previous quarter improving PAT margin
“Interest costs declined to ₹1.49 crores in Q3 FY26 from ₹3.04 crores in the previous quarter, providing some relief to the bottom line”
What: Tax rate expected to return to historical average of 29.46% from elevated 39.41% in Q3
“The tax rate for Q3 FY26 stood at 39.41%, significantly higher than the 29.63% in Q2 FY26 and above the company's average tax rate of 29.46%”
Earnings deceleration risks from management commentary
Trigger: Other income remains above 30% of PBT
Impact: -200 bps margin impact
Management view: The quarter's performance was significantly influenced by volatile other income, which surged to ₹18.46 crores in Q3 FY26 from ₹8.46 crores in the previous quarter.
Monitor: Other income as % of PBT
Trigger: Raw material costs increase or pricing pressure intensifies
Impact: -150 bps margin impact
Management view: Not directly addressed in available sources
Monitor: Operating margin (excl. other income)
Trigger: Inconsistent demand patterns continue
Impact: -100 bps margin impact
Management view: Not directly addressed in available sources
Monitor: Sequential revenue growth
Key quotes from recent conference calls
“Nine-month consolidated operations showed strong growth with 32.78% increase in net profit to ₹9,772.90 lakh and 15.13% revenue growth to ₹73,248.81 lakh — Management”
“Interest costs declined to ₹1.49 crores in Q3 FY26 from ₹3.04 crores in the previous quarter, providing some relief to the bottom line — Management”
“The tax rate for Q3 FY26 stood at 39.41%, significantly higher than the 29.63% in Q2 FY26 and above the company's average tax rate of 29.46% — Management”
Forward-looking targets from management for Next 2-4 quarters
Key Milestones
• Tax rate normalization to historical average
• Interest cost management
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +4% | +3% | Stable |
| PAT (Net Profit) | -4% | +58% | Inflection Down |
| OPM | 16.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Bliss GVS Pharma Ltd's latest quarterly results (Dec 2025) show
Bliss GVS Pharma Ltd's profit is declining with an inflecting downward trend.
Bliss GVS Pharma Ltd's revenue growth trend is stable.
Bliss GVS Pharma Ltd's operating margin is stable.
Bliss GVS Pharma Ltd's long-term compounding rates
Bliss GVS Pharma Ltd's earnings growth is inflecting downward with mixed signals on a sequential basis.
Bliss GVS Pharma Ltd's trailing twelve month (TTM) performance
Bliss GVS Pharma Ltd appears slightly undervalued based on our fair value analysis.
Bliss GVS Pharma Ltd's current PE ratio is 20.9x.
Bliss GVS Pharma Ltd's current PE is 20.9x.
Bliss GVS Pharma Ltd's price-to-book ratio is 2.0x.
Bliss GVS Pharma Ltd is rated Average with a fundamental score of 42.46/100. This score is calculated from objective financial metrics
Bliss GVS Pharma Ltd has a debt-to-equity ratio of N/A.
Bliss GVS Pharma Ltd's return ratios over recent years
Bliss GVS Pharma Ltd's operating cash flow is positive (FY2025).
Bliss GVS Pharma Ltd's current dividend yield is 0.23%.
Bliss GVS Pharma Ltd's shareholding pattern (Dec 2025)
Bliss GVS Pharma Ltd's promoter holding has decreased recently.
Bliss GVS Pharma Ltd has been outperforming Nifty 500 for 9 consecutive weeks, indicating consistent outperformance.
Bliss GVS Pharma Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Bliss GVS Pharma Ltd has 3 key growth catalysts identified from recent earnings analysis
Bliss GVS Pharma Ltd has 3 key risks worth monitoring
In Q3 FY26, Bliss GVS Pharma Ltd's management highlighted
Bliss GVS Pharma Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Bliss GVS Pharma Ltd may be worth studying
Bliss GVS Pharma Ltd investment thesis summary:
Bliss GVS Pharma Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
